Systematic Review of the Economic Evaluation of Sodium–Glucose Cotransporter-2 Inhibitors Used as Treatment in Patients with Heart Failure

[1]  G. Fonarow,et al.  Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction. , 2023, JAMA cardiology.

[2]  D. Nitta,et al.  Cost-effectiveness analysis of Empagliflozin in patients with heart failure with reduced ejection fraction in Japan based on the EMPEROR-reduced trial. , 2023, Journal of cardiology.

[3]  H. V. Nguyen,et al.  Cost-effectiveness of dapagliflozin and empagliflozin for treatment of heart failure with reduced ejection fraction. , 2023, International journal of cardiology.

[4]  D. Sim,et al.  Cost-Effectiveness of Empagliflozin on Top of Standard of Care for Heart Failure With Reduced Ejection Fraction in Singapore. , 2023, Value in health regional issues.

[5]  J. McMurray,et al.  Cost‐effectiveness of immediate initiation of dapagliflozin in patients with a history of heart failure , 2023, European journal of heart failure.

[6]  V. Harjola,et al.  Cost-Effectiveness of Empagliflozin in Combination with Standard Care versus Standard Care Only in the Treatment of Heart Failure Patients in Finland , 2023, ClinicoEconomics and outcomes research : CEOR.

[7]  A. Tafazzoli,et al.  A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction , 2022, The European Journal of Health Economics.

[8]  Shenmin Zhang,et al.  Cost-effectiveness of empagliflozin for the treatment of heart failure with reduced ejection fraction in China , 2022, Frontiers in Cardiovascular Medicine.

[9]  J. Spertus,et al.  Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction. , 2022, JAMA internal medicine.

[10]  Haiqiang Sang,et al.  Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China , 2022, Frontiers in Pharmacology.

[11]  Yake Lou,et al.  Cost-Effectiveness of Adding Empagliflozin to Standard Treatment for Heart Failure with Preserved Ejection Fraction Patients in China , 2022, American Journal of Cardiovascular Drugs.

[12]  D. Stub,et al.  Cost-Effectiveness of Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction , 2022, Circulation. Cardiovascular quality and outcomes.

[13]  Jun Xie,et al.  Cost-effectiveness of adding empagliflozin to the standard therapy for Heart Failure with Preserved Ejection Fraction from the perspective of healthcare systems in China , 2022, Frontiers in Cardiovascular Medicine.

[14]  R. Krittayaphong,et al.  Cost-Utility Analysis of Combination Empagliflozin and Standard Treatment Versus Standard Treatment Alone in Thai Heart Failure Patients with Reduced or Preserved Ejection Fraction , 2022, American Journal of Cardiovascular Drugs.

[15]  Feng Xie,et al.  Industry sponsorship bias in cost effectiveness analysis: registry based analysis , 2022, BMJ.

[16]  N. Brunetti,et al.  Pharmacological Anti-Remodelling Effects of Disease-Modifying Drugs in Heart Failure with Reduced Ejection Fraction , 2022, Clinical Drug Investigation.

[17]  Addendum. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022. Diabetes Care 2022;45(Suppl. 1):S144-S174. , 2022, Diabetes care.

[18]  Chongqing Tan,et al.  Economic Evaluation of Dapagliflozin in the Treatment of Patients With Heart Failure: A Systematic Review , 2022, Frontiers in Pharmacology.

[19]  A. M. Seyam,et al.  Dapagliflozin cost-effectiveness analysis in heart failure patients in Egypt , 2022, Journal of medical economics.

[20]  Dave L Dixon,et al.  2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. , 2022, Journal of cardiac failure.

[21]  G. Sinagra,et al.  [ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: what's new?] , 2022, Giornale italiano di cardiologia.

[22]  Deepak L. Bhatt,et al.  Alirocumab after acute coronary syndrome in patients with a history of heart failure , 2021, European heart journal.

[23]  Introduction: Standards of Medical Care in Diabetes-2022. , 2021, Diabetes care.

[24]  E. Huang,et al.  10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022. , 2021, Diabetes care.

[25]  H. Khamis,et al.  Egyptian Atherosclerosis and Vascular Biology Association Consensus on the Use of Sodium Glucose Cotransporter-2 Inhibitors in Heart Failure with Reduced Ejection Fraction , 2021, Clinical Drug Investigation.

[26]  Yaohui Jiang,et al.  Cost-Effectiveness of Adding SGLT2 Inhibitors to Standard Treatment for Heart Failure With Reduced Ejection Fraction Patients in China , 2021, Frontiers in Pharmacology.

[27]  C. Strong,et al.  Cost-Effectiveness Evaluation of Add-on Empagliflozin in Patients With Heart Failure and a Reduced Ejection Fraction From the Healthcare System's Perspective in the Asia-Pacific Region , 2021, Frontiers in Cardiovascular Medicine.

[28]  P. Lasalvia,et al.  Cost-utility of dapagliflozin plus standard treatment compared to standard treatment for the management of heart failure with reduced ejection fraction in Colombia , 2021, Expert review of pharmacoeconomics & outcomes research.

[29]  R. Arbel,et al.  Dapagliflozin Versus Sacubitril–Valsartan to Improve Outcomes of Patients with Reduced Ejection Fraction and Diabetes Mellitus , 2021, American Journal of Cardiovascular Drugs.

[30]  C. Strong,et al.  Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia–Pacific region , 2021, Cardiovascular Diabetology.

[31]  T. Akasaka,et al.  JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure. , 2021, Circulation journal : official journal of the Japanese Circulation Society.

[32]  F. Punzalan,et al.  Cost‐utility analysis of add‐on dapagliflozin in heart failure with reduced ejection fraction in the Philippines , 2021, ESC heart failure.

[33]  G. Úrrutia,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. , 2021, Revista espanola de cardiologia.

[34]  J. McMurray,et al.  2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. , 2021, European heart journal.

[35]  P. Ponikowski,et al.  Empagliflozin in Heart Failure with a Preserved Ejection Fraction. , 2021, The New England journal of medicine.

[36]  B. Bellows,et al.  Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction , 2021, JAMA network open.

[37]  Sanjiv J. Shah,et al.  Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial , 2021, European journal of heart failure.

[38]  J. Spertus,et al.  Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction. , 2021, JAMA cardiology.

[39]  A. Kansal,et al.  Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease , 2021, BMJ Open Diabetes Research & Care.

[40]  Xiaodong Lin,et al.  Cost-effectiveness of empagliflozin as a treatment for heart failure with reduced ejection fraction: an analysis from the Chinese healthcare perspective , 2021, Journal of Thoracic Disease.

[41]  R. Arbel,et al.  Dapagliflozin vs. sacubitril-valsartan for prevention of heart failure events in non-diabetic patients with reduced ejection fraction: a cost per outcome analysis. , 2020, European journal of preventive cardiology.

[42]  Deepak L. Bhatt,et al.  Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. , 2020, The New England journal of medicine.

[43]  Jian Zhang,et al.  Cost‐effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China , 2020, ESC heart failure.

[44]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2020, BMJ.

[45]  P. Ponikowski,et al.  Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. , 2020, The New England journal of medicine.

[46]  R. Krittayaphong,et al.  Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction. , 2020, International journal of cardiology.

[47]  J. McMurray,et al.  Cost‐effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health‐economic analysis of DAPA‐HF , 2020, European journal of heart failure.

[48]  Z. Ademi,et al.  Cost-effectiveness of dapagliflozin in chronic heart failure: an analysis from the Australian healthcare perspective. , 2020, European journal of preventive cardiology.

[49]  H. Lao,et al.  Cost-effectiveness analyses of sacubitril-valsartan for heart failure , 2020, Heart Failure Reviews.

[50]  Lizheng Shi,et al.  A Systematic Review of Cost-Effectiveness of Sodium-Glucose Cotransporter Inhibitors for Type 2 Diabetes , 2020, Current diabetes reports.

[51]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[52]  B. Akıncı.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. , 2019, The New England journal of medicine.

[53]  Gerui Li,et al.  Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Meta-Analysis of Randomized Controlled Trials , 2019, Clinical Drug Investigation.

[54]  M. Jiang,et al.  Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review , 2019, PharmacoEconomics.

[55]  Deepak L. Bhatt,et al.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019, The New England journal of medicine.

[56]  M. Pfeffer,et al.  Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality , 2018, European journal of heart failure.

[57]  R. Guthrie.  Canagliflozin and cardiovascular and renal events in type 2 diabetes , 2018, Postgraduate medicine.

[58]  S. Jan,et al.  Economic evaluation of medicines. , 2017, Australian prescriber.

[59]  M. Fischereder,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2016, The New England journal of medicine.

[60]  Christine Y. Lu,et al.  Barriers to access and use of high cost medicines: A review , 2015 .

[61]  D. McManus,et al.  Long-term survival for patients with acute decompensated heart failure according to ejection fraction findings. , 2014, The American journal of cardiology.

[62]  J. Piette,et al.  A conceptually based approach to understanding chronically ill patients' responses to medication cost pressures. , 2006, Social science & medicine.

[63]  Eve A Kerr,et al.  The role of patient-physician trust in moderating medication nonadherence due to cost pressures. , 2005, Archives of internal medicine.

[64]  T. Wagner,et al.  Clinician identification of chronically ill patients who have problems paying for prescription medications. , 2004, The American journal of medicine.

[65]  Harlan M Krumholz,et al.  The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure. , 2003, Journal of the American College of Cardiology.

[66]  J. Hay,et al.  Examining the Value and Quality of Health Economic Analyses: Implications of Utilizing the QHES , 2003, Journal of managed care pharmacy : JMCP.

[67]  P. Easterbrook,et al.  Publication bias in clinical research , 1991, The Lancet.

[68]  M. Hoyle.  Future Drug Prices and Cost-Effectiveness Analyses , 2012, PharmacoEconomics.